PharmExec Blog
Follow Us
RSS
Bookstore
Tag Archives: Strategy
Pharma Complexity Is Leading to Loss of Profits
It will take far more than factory closures to simplify the pharma industry, write Melvin Jay and Professor Simon Collinson.
When pharmaceutical giant Novartis announced it was likely to close its West Sussex (UK) factory, it came as no surprise to the pharmaceutical industry — as Pfizer, AstraZeneca and Glaxo had done the same. While these [...]
Former EMA Head Back in the Regulatory Saddle
His decade-long tenure as head of the European Medicines Agency (EMA) may have ended, but Thomas Lönngren is already back in the regulatory saddle as a strategic advisor to NDA Group, an independent consulting group focused on reducing wasted drug development costs, ensuring new medicines get to market faster, and “improving the performance of the [...]
Posted in Europe, Global, Market Access, People, R&D, Regulatory, leadership, pricing Also tagged EMA, Market Access, Regulatory, Thomas Lönngren Leave a comment
GE Capital CFO Survey Reveals State of Pharma Industry in 2010, 2011
Industry CFOs are driving much of the current strategy of big pharma, which is to push costs of administration and selling down to compensate for low rates of organic growth through new product introductions. This survey of their views is timely and important in gauging the direction of pharma strategy in the next year.
Last week, GE [...]
Alliance Management is Being Neglected, Says Study
Survey finds disconnect between perceived importance of alliance management function at C-level and actual commitment to it.
The Rhythm of Business has released the results of a recent study titled The Practice of Alliance Management in the Biopharmaceutical Industry that examines the state of alliance management in pharmaceutical companies. The study, co-sponsored by the Biopharma Council [...]
Doing More With Less: A Leadership Perspective